Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Savica
Vincenzo
V
Department of Nephrology, University of Messina and Nephrology Dialysis Unit 'Papardo' Hospital, Messina, Italy.
Calò
Lorenzo A
LA
Monardo
Pietro
P
Santoro
Domenico
D
Bellinghieri
Guido
G
D000085:Acetates / Q000627:therapeutic use; D017607:Aluminum Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000517:prevention & control; D002114:Calcinosis / Q000209:etiology / Q000517:prevention & control; D002119:Calcium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D017610:Calcium Compounds / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology / Q000517:prevention & control; D018753:Diet, Protein-Restricted; D005290:Ferric Compounds / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000178:diet therapy / Q000628:therapy; D007811:Lanthanum / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood*; D016226:Phosphorus, Dietary / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D011073:Polyamines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006435:Renal Dialysis; D000069603:Sevelamer
D000085:Acetates; D017607:Aluminum Compounds; D017610:Calcium Compounds; D005290:Ferric Compounds; D010710:Phosphates; D016226:Phosphorus, Dietary; D011073:Polyamines; C021024:ferric hydroxide; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; D002119:Calcium Carbonate; C120662:calcium acetate